{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:24:11Z","timestamp":1793665451507,"version":"4.5.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Inflammation is increasingly recognized as a critical factor in acute myeloid leukemia (AML) pathogenesis. We performed blood-based proteomic profiling of 251 inflammatory proteins in 543 patients with newly diagnosed AML. Using a machine learning model, we derived an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS). Individual proteins were evaluated in multivariable Cox models, and model performance was assessed by cumulative concordance index. Findings were validated in internal and external cohorts across 2 institutions. Blood-based LIRS significantly outperformed the European LeukemiaNet 2022 risk model and was independently prognostic of overall survival after accounting for known clinical and molecular prognostic factors. Oncostatin M receptor was uniquely identified as the strongest independent predictor of survival, early mortality, and induction chemotherapy response, and further validated in an independent assay. These blood-based biomarkers could have significant clinical implications for risk stratification and prognostication in patients with newly diagnosed AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027244","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T20:28:45Z","timestamp":1743798525000},"page":"3015-3029","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8433-3360","authenticated-orcid":false,"given":"Patrick K.","family":"Reville","sequence":"first","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-6802","authenticated-orcid":false,"given":"Bofei","family":"Wang","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9595-1279","authenticated-orcid":false,"given":"Jennifer","family":"Marvin-Peek","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yuan","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1002-3201","authenticated-orcid":false,"given":"Yu-An","family":"Kuo","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Garza","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Root","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[{"name":"2Division of Discovery Science, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Arruda","sequence":"additional","affiliation":[{"name":"3Department of Medical Biophysics, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-5313","authenticated-orcid":false,"given":"Ivo","family":"Veletic","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-6269","authenticated-orcid":false,"given":"Yiwei","family":"Liu","sequence":"additional","affiliation":[{"name":"4Division of Discovery Science, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-7774","authenticated-orcid":false,"given":"Philip L.","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"4Division of Discovery Science, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kornblau","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-8816","authenticated-orcid":false,"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[{"name":"3Department of Medical Biophysics, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-3562","authenticated-orcid":false,"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"5Division of Cancer Medicine, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2025061911213688700_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2025061911213688700_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025061911213688700_bib3","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"33","key":"2025061911213688700_bib4","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025061911213688700_bib5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025061911213688700_bib6","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"12","key":"2025061911213688700_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025061911213688700_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2025061911213688700_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.26395","article-title":"Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy","volume":"97","author":"Sasaki","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"2025061911213688700_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cncr.34609","article-title":"Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"issue":"6","key":"2025061911213688700_bib11","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"2025061911213688700_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"4","key":"2025061911213688700_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2643-3230.BCD-22-0176","article-title":"The role of inflammation in the initiation and progression of myeloid neoplasms","volume":"4","author":"Balandr\u00e1n","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025061911213688700_bib14","first-page":"149","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"2025061911213688700_bib15","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"2025061911213688700_bib16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2023.13258","article-title":"Evaluation of large-scale proteomics for prediction of cardiovascular events","volume":"330","author":"Helgason","year":"2023","journal-title":"JAMA"},{"issue":"7982","key":"2025061911213688700_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","article-title":"Large-scale plasma proteomics comparisons through genetics and disease associations","volume":"622","author":"Eldjarn","year":"2023","journal-title":"Nature"},{"issue":"7982","key":"2025061911213688700_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"3","key":"2025061911213688700_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-023-02790-x","article-title":"Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"2025061911213688700_bib20","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41591-024-03092-6","article-title":"A unified metric of human immune health","volume":"30","author":"Sparks","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"2025061911213688700_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","article-title":"Plasma proteomic profiles predict future dementia in healthy adults","volume":"4","author":"Guo","year":"2024","journal-title":"Nat Aging"},{"issue":"18","key":"2025061911213688700_bib22","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2023023593","article-title":"IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation","volume":"143","author":"Hong","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2025061911213688700_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-018-0107-2","article-title":"Clonal hematopoiesis in patients with rheumatoid arthritis","volume":"8","author":"Savola","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025061911213688700_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.beha.2019.02.002","article-title":"Myeloid disorders after autoimmune disease","volume":"32","author":"Boddu","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2025061911213688700_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"2025061911213688700_bib26","doi-asserted-by":"crossref","first-page":"e20201544","DOI":"10.1084\/jem.20201544","article-title":"Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS","volume":"218","author":"Trowbridge","year":"2021","journal-title":"J Exp Med"},{"issue":"546","key":"2025061911213688700_bib27","doi-asserted-by":"crossref","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"issue":"15","key":"2025061911213688700_bib28","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025061911213688700_bib29","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","article-title":"NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","volume":"14","author":"Feng","year":"2023","journal-title":"Nat Commun"},{"key":"2025061911213688700_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: An R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinformatics"},{"issue":"21","key":"2025061911213688700_bib31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025061911213688700_bib32","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","article-title":"Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"issue":"17","key":"2025061911213688700_bib33","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1182\/blood-2008-12-191478","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025061911213688700_bib34","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?","volume":"136","author":"R\u00f6llig","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2025061911213688700_bib35","first-page":"e106","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"2025061911213688700_bib36","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/ijms20174195","article-title":"The role of fibroblast growth factor 23 in inflammation and anemia","volume":"20","author":"Czaya","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025061911213688700_bib37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12967-023-04782-4","article-title":"Role of IL-33-ST2 pathway in regulating inflammation: current evidence and future perspectives","volume":"21","author":"Zhou","year":"2023","journal-title":"J Transl Med"},{"issue":"2","key":"2025061911213688700_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3892\/etm.2020.9594","article-title":"Inflammatory signals induce MUC16 expression in ovarian cancer cells via NF-\u03baB activation","volume":"21","author":"Liu","year":"2021","journal-title":"Exp Ther Med"},{"key":"2025061911213688700_bib39","doi-asserted-by":"crossref","first-page":"4087315","DOI":"10.1155\/2020\/4087315","article-title":"IL-33 mediates lung inflammation by the IL-6-type cytokine oncostatin M","volume":"2020","author":"Botelho","year":"2020","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2025061911213688700_bib40","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1038\/s41598-023-34858-6","article-title":"Oncostatin M is a regulator of fibroblast growth factor 23 (FGF23) in UMR106 osteoblast-like cells","volume":"13","author":"M\u00fcnz","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"2025061911213688700_bib41","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.3390\/ijms21124365","article-title":"Biological functions and therapeutic potential of lipocalin 2 in cancer","volume":"21","author":"Santiago-S\u00e1nchez","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025061911213688700_bib42","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41598-021-04127-5","article-title":"GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence","volume":"12","author":"Uceda-Castro","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"2025061911213688700_bib43","doi-asserted-by":"crossref","first-page":"13426","DOI":"10.1002\/cam4.5970","article-title":"Visinin-like 1, a novel target gene of the Wnt\/\u03b2-catenin signaling pathway, is involved in apoptosis resistance in colorectal cancer","volume":"12","author":"Tage","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"2025061911213688700_bib44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cytogfr.2015.07.006","article-title":"Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology","volume":"26","author":"Hermanns","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"issue":"24","key":"2025061911213688700_bib45","doi-asserted-by":"crossref","first-page":"15135","DOI":"10.1074\/jbc.272.24.15135","article-title":"Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6","volume":"272","author":"Kuropatwinski","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"2025061911213688700_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cellsig.2005.03.015","article-title":"Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases","volume":"18","author":"B\u00f6ing","year":"2006","journal-title":"Cell Signal"},{"issue":"9","key":"2025061911213688700_bib47","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2003-02-0367","article-title":"Targeted disruption of oncostatin M receptor results in altered hematopoiesis","volume":"102","author":"Tanaka","year":"2003","journal-title":"Blood"},{"key":"2025061911213688700_bib48","doi-asserted-by":"crossref","first-page":"104131","DOI":"10.1016\/j.exphem.2023.11.005","article-title":"Transcriptional and functional consequences of Oncostatin M signaling on young Dnmt3a-mutant hematopoietic stem cells","volume":"130","author":"Schwartz","year":"2024","journal-title":"Exp Hematol"},{"issue":"suppl 1","key":"2025061911213688700_bib49","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2024-207654","article-title":"STAT5-activating oncogenes drive oncostatin M production causing T cell exhaustion and suppressive myeloid cell recruitment [abstract]","volume":"144","author":"Rassner","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/25\/3015\/2380238\/blood_bld-2024-027244-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/25\/3015\/2380238\/blood_bld-2024-027244-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:21:48Z","timestamp":1750332108000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/25\/3015\/536513\/Blood-based-proteomic-profiling-identifies-OSMR-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":49,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,6,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027244","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,19]]},"published":{"date-parts":[[2025,6,19]]}}}